Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide

In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections of mature DC loaded with autologous GBM ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellegatta, Serena, Eoli, Marica, Cuccarini, Valeria, Anghileri, Elena, Pollo, Bianca, Pessina, Sara, Frigerio, Simona, Servida, Maura, Cuppini, Lucia, Antozzi, Carlo, Cuzzubbo, Stefania, Corbetta, Cristina, Paterra, Rosina, Acerbi, Francesco, Ferroli, Paolo, DiMeco, Francesco, Fariselli, Laura, Parati, Eugenio A., Bruzzone, Maria Grazia, Finocchiaro, Gaetano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889286/
https://www.ncbi.nlm.nih.gov/pubmed/29632727
http://dx.doi.org/10.1080/2162402X.2017.1412901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889286/
https://www.ncbi.nlm.nih.gov/pubmed/29632727
http://dx.doi.org/10.1080/2162402X.2017.1412901

Ejemplares similares